Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.1117
Abstract: This cross-sectional study examines utilization trends for filgrastim and infliximab products and their biosimilars to understand whether biosimilars are associated with reduced spending in Medicare Part D. read more here.
Keywords: medicare part; biosimilar products; utilization filgrastim; infliximab biosimilar ... See more keywords
Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09234-y
Abstract: ObjectivesInfliximab is increasingly used to treat neurosarcoidosis. We aimed to determine the efficacy and tolerance of an infliximab biosimilar for treating neurosarcoidosis.MethodsWe conducted a retrospective single-center study to describe the efficacy, safety and immunogenicity of… read more here.
Keywords: originator; treatment; efficacy; treating neurosarcoidosis ... See more keywords
Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience
Sign Up to like & getrecommendations! Published in 2018 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2018.1464203
Abstract: Abstract Objectives: Recently, the infliximab biosimilar (CT-P13) received market authorisation for inflammatory bowel disease (IBD), allowing cost benefits when switching to CT-P13. We aim to assess the efficacy and safety of switching from originator infliximab… read more here.
Keywords: response; originator; efficacy; infliximab originator ... See more keywords
Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2022.2090275
Abstract: Abstract Objective Project NORTH compared real-world clinical and economic outcomes in Swedish patients with inflammatory bowel disease (IBD) who switched from originator infliximab to its biosimilar. Materials and methods Data from electronic medical records and… read more here.
Keywords: disease; non switchers; originator infliximab; infliximab biosimilar ... See more keywords
Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2020.1803889
Abstract: Abstract Aims This study aimed to conduct a cost-effectiveness analysis of infliximab and its biosimilar compared to conventional therapy in refractory moderate-to-severe Crohn’s disease (CD) in Thailand. Materials and methods A Markov model was used… read more here.
Keywords: budget impact; cost; infliximab biosimilar;
P672 Occurrence of malignancy among infliximab biosimilar and bio-originator initiators in Canada: a comparative population-based analysis
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0802
Abstract: Infliximab (INF) downregulates the immune system. Given the immune system's role in deleting pre-cancerous cells, malignancy is a potential concern. Still, relatively few real-world data analyses have compared biosimilar versus bio-originator INF in terms of… read more here.
Keywords: system; bio originator; malignancy; inf ... See more keywords
Rapid Infliximab Biosimilar Infusion in Children with Inflammatory Bowel Disease.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of pediatric gastroenterology and nutrition"
DOI: 10.1097/mpg.0000000000003402
Abstract: OBJECTIVES Compare prevalence of infusion reaction (IR) between infliximab (IFX) and infliximab biosimilar (IFX-abda) at standard and rapid rates and measure the impact on health care cost in children with inflammatory bowel disease. METHODS Records… read more here.
Keywords: inflammatory bowel; infusion; ifx abda; children inflammatory ... See more keywords
Clinical experience with infliximab biosimilar in psoriasis
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Dermatology"
DOI: 10.1111/bjd.15755
Abstract: biosimilar medicines are biological medicine that have been developed to be highly similar and clinically equivalent to an existing biological medicine. Just as patent expiry for conventional drugs has led to the marketing of generic… read more here.
Keywords: medicine; dermatology; experience infliximab; clinical experience ... See more keywords
Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Dermatology"
DOI: 10.1111/bjd.19013
Abstract: CT-P13 and SB2 are two distinct biosimilars of the reference originator anti-tumour necrosis factor alpha monoclonal antibody infliximab. Real-life evidence has shown that the switch from infliximab originator to CT-P13 did not impair overall clinical… read more here.
Keywords: infliximab; chronic plaque; p13; sb2 ... See more keywords
Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-214374
Abstract: To date, all available data regarding the switch from bio-originator to its biosimilar are reassuring, and the switch has been recommended as a shared patient–physician decision in recent consensus-based recommendations.1 In particular, the Norway's infliximab… read more here.
Keywords: originator; long term; term follow; originator infliximab ... See more keywords
Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
Sign Up to like & getrecommendations! Published in 2019 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s170913
Abstract: Background Infliximab (Remicade), a chimeric monoclonal antibody against human TNFα, will inevitably face competition from biosimilar products, because of its effectiveness in autoimmune diseases and rapidly increasing market demand. According to guidelines for biosimilar development,… read more here.
Keywords: expression; expression system; cmab008 infliximab; infliximab biosimilar ... See more keywords